Loading...

Ypsomed Holding AG

YPSN.SW•SIX
Healthcare
Medical - Instruments & Supplies
CHF416.50
CHF-4.50(-1.07%)

Ypsomed Holding AG (YPSN.SW) Stock Overview

Explore Ypsomed Holding AG’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

F

Score: N/A

Key Financials

Market Cap5.7B
P/E Ratio65.01
EPS (TTM)$6.42
ROE0.13%
Fundamental Analysis

AI Price Forecasts

1 Week$437.68
1 Month$438.94
3 Months$334.53
1 Year Target$452.55

YPSN.SW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Ypsomed Holding AG (YPSN.SW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 65.03, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $452.55.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 65.01 and a market capitalization of 5.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

65.03RSI (14)
7.42MACD
40.64ADX
Stats data is not available for YPSN.SWStats details for YPSN.SW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for YPSN.SWAnalyst Recommendations details for YPSN.SW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, patch injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through biotechnology and pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.

CEO

Simon Michel

Employees

2,600

Headquarters

Brunnmattstrasse 6, Burgdorf

Founded

2004

Frequently Asked Questions

;